Assessment of DCE Utility for PCa Diagnosis Using PI-RADS v2.1: Effects on Diagnostic Accuracy and Reproducibility
- PMID: 32192081
- PMCID: PMC7151226
- DOI: 10.3390/diagnostics10030164
Assessment of DCE Utility for PCa Diagnosis Using PI-RADS v2.1: Effects on Diagnostic Accuracy and Reproducibility
Abstract
The role of dynamic contrast-enhanced-MRI (DCE-MRI) for Prostate Imaging-Reporting and Data System (PI-RADS) scoring is a controversial topic. In this retrospective study, we aimed to measure the added value of DCE-MRI in combination with T2-weighted (T2W) and diffusion-weighted imaging (DWI) using PI-RADS v2.1, in terms of reproducibility and diagnostic accuracy, for detection of prostate cancer (PCa) and clinically significant PCa (CS-PCa, for Gleason Score ≥ 7). 117 lesions in 111 patients were identified as suspicion by multiparametric MRI (mpMRI) and addressed for biopsy. Three experienced readers independently assessed PI-RADS score, first using biparametric MRI (bpMRI, including DWI and T2W), and then multiparametric MRI (also including DCE). The inter-rater and inter-method agreement (bpMRI- vs. mpMRI-based scores) were assessed by Cohen's kappa (κ). Receiver operating characteristics (ROC) analysis was performed to evaluate the diagnostic accuracy for PCa and CS-PCa detection among the two scores. Inter-rater agreement was excellent for the three pairs of readers (κ ≥ 0.83), while the inter-method agreement was good (κ ≥ 0.73). Areas under the ROC curve (AUC) showed similar high-values (0.8 ≤ AUC ≤ 0.85). The reproducibility of PI-RADS v2.1 scoring was comparable and high among readers, without relevant differences, depending on the MRI protocol used. The inclusion of DCE did not influence the diagnostic accuracy.
Keywords: DCE; PI-RADS; ROC analysis; magnetic resonance imaging; mpMRI; prostate cancer; reproducibility.
Conflict of interest statement
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Figures

Similar articles
-
Comparison of Biparametric and Multiparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2.1.J Magn Reson Imaging. 2021 Jan;53(1):283-291. doi: 10.1002/jmri.27283. Epub 2020 Jul 2. J Magn Reson Imaging. 2021. PMID: 32614123
-
Comparison of biparametric and multiparametric MRI in the diagnosis of prostate cancer.Cancer Imaging. 2019 Dec 21;19(1):90. doi: 10.1186/s40644-019-0274-9. Cancer Imaging. 2019. PMID: 31864408 Free PMC article.
-
Prostate cancer detection with biparametric magnetic resonance imaging (bpMRI) by readers with different experience: performance and comparison with multiparametric (mpMRI).Abdom Radiol (NY). 2019 May;44(5):1883-1893. doi: 10.1007/s00261-019-01934-3. Abdom Radiol (NY). 2019. PMID: 30788558
-
Current Status of Biparametric MRI in Prostate Cancer Diagnosis: Literature Analysis.Life (Basel). 2022 May 28;12(6):804. doi: 10.3390/life12060804. Life (Basel). 2022. PMID: 35743835 Free PMC article. Review.
-
Is contrast enhancement needed for diagnostic prostate MRI?Transl Androl Urol. 2017 Jun;6(3):499-509. doi: 10.21037/tau.2017.05.31. Transl Androl Urol. 2017. PMID: 28725592 Free PMC article. Review.
Cited by
-
Predicting prostate cancer in men with PSA levels of 4-10 ng/mL: MRI-based radiomics can help junior radiologists improve the diagnostic performance.Sci Rep. 2023 Mar 24;13(1):4846. doi: 10.1038/s41598-023-31869-1. Sci Rep. 2023. PMID: 36964192 Free PMC article.
-
Usefulness of Collaborative Work in the Evaluation of Prostate Cancer from MRI.Clin Pract. 2022 May 20;12(3):350-362. doi: 10.3390/clinpract12030040. Clin Pract. 2022. PMID: 35645317 Free PMC article.
-
[Prostate Imaging Reporting and Data System (PI-RADS) v 2.1: Overview and Critical Points].J Korean Soc Radiol. 2023 Jan;84(1):75-91. doi: 10.3348/jksr.2022.0169. Epub 2023 Jan 30. J Korean Soc Radiol. 2023. PMID: 36818694 Free PMC article. Review. Korean.
-
A semi-automatic deep learning model based on biparametric MRI scanning strategy to predict bone metastases in newly diagnosed prostate cancer patients.Front Oncol. 2024 Jun 11;14:1298516. doi: 10.3389/fonc.2024.1298516. eCollection 2024. Front Oncol. 2024. PMID: 38919538 Free PMC article.
-
Risk score model to automatically detect prostate cancer patients by integrating diagnostic parameters.Front Oncol. 2024 May 15;14:1323247. doi: 10.3389/fonc.2024.1323247. eCollection 2024. Front Oncol. 2024. PMID: 38873254 Free PMC article.
References
-
- Hegde J.V., Mulkern R.V., Panych L.P., Fennessy F.M., Fedorov A., Maier S.E., Tempany C.M. Multiparametric MRI of prostate cancer: An update on state-of-the-art techniques and their performance in detecting and localizing prostate cancer. J. Magn. Reson. Imaging. 2013;37:1035–1054. doi: 10.1002/jmri.23860. - DOI - PMC - PubMed
-
- Futterer J.J., Briganti A., De Visschere P., Emberton M., Giannarini G., Kirkham A., Taneja S.S., Thoeny H., Villeirs G., Villers A. Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. Eur. Urol. 2015;68:1045–1053. doi: 10.1016/j.eururo.2015.01.013. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous